SAMHD1 and carcinoma: In human carcinoma and osteosarcoma cell lines, SAMHD1 overexpression decreased the efficacy of DSB-inducing drugs such as topoisomerase inhibitors or IR, while SAMHD1 depletion was associated with increased efficacy of these treatments23.